Skip to main content
. 2022 Aug;192(8):1186–1198. doi: 10.1016/j.ajpath.2022.05.005

Figure 1.

Figure 1

Hairy and enhancer of split homolog-1 (HES1) is expressed in anaplastic lymphoma kinase–positive (ALK+) T cells and tissues. A: mRNA expression of HES1 in ALK+ T-cell lymphoma (TCL)–derived cell lines (SUDHL-1 and SUP-M2), nucleophosmin (NPM)–ALK–transformed CD4+ T cells (NA1), and control cell populations [resting peripheral blood mononuclear cells (PBMCs) and activated PBMCs/PHA] detected by DNA oligonucleotide array analysis. The data are depicted as units of the normalized signal intensity. B: Expression of HES1 mRNA in the depicted ALK+ TCL cell lines, NA1, and control PBMC/PHA cells detected by quantitative RT-PCR (RT-qPCR). The results depict fold difference compared with control, after signal intensity normalization. C: Expression of HES1 protein in the depicted ALK+ T-cell and control populations, identified by Western blot analysis. D: Subcellular localization of HES1 in NPM-ALK–positive cells. Nuclear and cytoplasmic protein fractions isolated from SUDHL-1 and SUP-M2 cells were resolved by SDS-PAGE and analyzed by Western blot analysis. Blots were stripped and reprobed with anti-YY1 antibody to control the purity of fractions. E: Expression of HES1 protein in ALK+ TCL tissues detected by immunohistochemistry (representative images). Staining with hematoxylin and eosin (H&E) and antibodies against ALK and CD30 served as positive controls, highlighting the large anaplastic malignant ALK+ TCL cells within the tissue. Original magnification: ×40 (E, main images); ×100 (E, insets). ACTB, β-actin; C, cytoplasm; CTCL, cutaneous T-cell lymphoma; N, nucleus; p-ALK, phosphorylated ALK.